Kalaris Therapeutics, Inc. (KLRS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $34.76M
Last updated: Nov 17, 2026 at 4:10 PM ET
Kalaris Therapeutics, Inc. (KLRS) Statistics
Kalaris Therapeutics (KLRS) has a market cap of $34.76M. Its share count is up 27.29% from a year earlier. It holds $47.38M more cash than debt, 136.34% of its market cap.
Total Valuation
| Market Cap | $34.76M |
|---|---|
| Latest price (Nov 17, 2026) | $1.43 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 73.81% over 52 weeks and trades 41.63% below its 50-day average.
| Beta (1Y) | 0.55 |
|---|---|
| 52-Week Change | -73.81% |
| 1-Month Change | -25.13% |
| 3-Month Change | -65.71% |
| 6-Month Change | -69.57% |
| 5-Year Change | -99.63% |
| Total Return (1Y) | -73.81% |
| Total Return (3Y CAGR) | -66.33% |
| Total Return (5Y CAGR) | -68.86% |
| Return vs SPY (1Y) | -89.39% |
| Max Drawdown (1Y) | -86.98% |
| Max Drawdown (3Y) | -97.40% |
| Sharpe Ratio (1Y) | -1.77 |
| Correlation with SPY (1Y) | 0.09 |
| 50-Day Average | $2.45 |
| 200-Day Average | $4.95 |
| 52-Week Range | $1.41 to $11.88 |
| RSI (14 Days) | 29.0 |
| Average Volume (20 Days) | 86.86K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 10.00x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 10.00x |
|---|---|
| Quick Ratio | 10.00x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -91.55% and return on assets is -48.76% over the last 12 months.
| Return on Equity (ROE) | -91.55% |
|---|---|
| Return on Assets (ROA) | -48.76% |
| Return on Capital Employed (ROCE) | -53.91% |
| ROIC (5Y Average) | -43.51% |
Scores
KLRS has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | -$10.00K |
| Operating Income | -$46.83M |
| Pretax Income | -$43.40M |
| Net Income | -$43.40M |
| EBIT | -$43.40M |
| Reported EPS (TTM) | -$1.84 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 53.26% of the $89.00M in total assets.
| Cash and Equivalents | $47.38M |
|---|---|
| Total Debt | $0 |
| Net Cash | $47.38M |
| Net Cash Per Share | $1.99 |
| Working Capital | $76.66M |
| Shareholder Equity | $47.40M |
| Book Value Per Share | $1.99 |
| Total Assets | $89.00M |
| Total Liabilities | $41.60M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$40.24M |
|---|---|
| FCF Per Share | -$1.69 |
| Depreciation and Amortization | $745.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -65.80% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -65.80% |
Stock Splits
The last split was a 1-for-23 reverse split on Jan 16, 2025.
| Last Split Date | Jan 16, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:23 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About KLRS
What is KLRS's market cap?
Kalaris Therapeutics has a market cap of $34.76M.
How many shares of KLRS are outstanding?
Kalaris Therapeutics has 23.80M shares outstanding. The count is up 27.29% from a year earlier.
Does KLRS pay a dividend?
No. Kalaris Therapeutics does not pay a dividend.
How much debt does KLRS have?
Kalaris Therapeutics has $0 of total debt and $47.38M of cash and equivalents, a net cash position of $47.38M.
KLRS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors